Use your antibodies-online credentials, if available.
抗Mouse (Murine) SRD5A1 抗体:
抗Human SRD5A1 抗体:
抗Rat (Rattus) SRD5A1 抗体:
Human Polyclonal SRD5A1 Primary Antibody for IHC (p), IHC - ABIN250339
Iczkowski, Qiu, Qian, Somerville, Rittmaster, Andriole, Bostwick: The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. in Urology 2005
Show all 8 Pubmed References
Human Polyclonal SRD5A1 Primary Antibody for WB - ABIN520464
Park, Aizawa, Iemitsu, Sato, Akimoto, Agata, Maeda, Ezawa, Omi: DHEA administration activates local bioactive androgen metabolism in cancellous site of tibia of ovariectomized rats. in Calcified tissue international 2011
Show all 3 Pubmed References
Human Polyclonal SRD5A1 Primary Antibody for IHC, ELISA - ABIN185346
Kapp, Sommer, Kiefer, Dölken, Haendler: 5-alpha-reductase type I (SRD5A1) is up-regulated in non-small cell lung cancer but does not impact proliferation, cell cycle distribution or apoptosis. in Cancer cell international 2012
Show all 2 Pubmed References
Prostate 5aR1 levels were positively correlated with adjusted prostate most severe lesion scores. Downregulation of androgen receptor and 5alpha-reductase 2, along with upregulation of 5a-reductase 1 in tumors may promote prostatic intraepithelial neoplasia and prostate cancer development in TRAMP mice
Exaggerated predisposition to metabolic disorders in female mice, compared with that seen in male mice, after disruption of 5alphaR1 suggests phenotypic changes may be underpinned by altered metabolism of glucocorticoids rather than androgens.
the Srd5a1 gene modulates ethanol consumption in a sex-dependent manner that is also contingent upon ethanol access condition and concentration
deletion of the Srd5a1 gene significantly decreased ethanol's anxiolytic effect in female mice, and chronic ethanol withdrawal severity was lower in female versus male mice
transcription of srd5a1 in brain is regulated by environmental factor-induced cytosine methylation in the promoter region.
The effects of deficiency or inhibition of S5AR1 on the risk of liver disease and insulin resistance in male rats and mice are reported.
The deletion of Type One 5alpha-reductase among female mice attenuates reproductive responding during the estrous cycle.
These studies showed that 5alphaR1 deletion accelerates the development of hepatic steatosis but may protect against the development of nonalcoholic fatty liver disease-related hepatocellular neoplasia.
Thus, 5alpha-reductase may be required for the estrous cycle variations in affective behavior and 3alpha,5alpha-THP levels of female mice.
results suggest that local steroid 5 alpha-reductase 1 messenger RNA expression in Withdrawal Seizure-Prone mouse brain may not change in parallel with local allopregnanolone content or withdrawal severity
The aim of the present study was to investigate the role of 5alpha-reductase type 1 for bone mass using Srd5a1-/- mice.
This study evaluates 5alpha-R type I and 3alpha-HSD mRNA expression level in mouse brain by using in situ hybridization.
social isolation-induced increase of the contextual fear-conditioning response is associated with a marked (50%) down-regulation of 5-RI mRNA expression in the hippocampus, amygdala, and FC.
Data suggests that in male mice after social isolation, expression of Srd5a1 mRNA is specifically down-regulated in glutamatergic pyramidal neurons. In socially isolated mice, this down-regulation may account for the appearance of behavioral disorders.
The study described in this article shows that selected SRD5A1 and SRD5A2 polymorphisms can alter the levels of metabolic and hormonal parameters in patients with BPH. Special attention should be paid to the SDR5A2 rs12470143 polymorphism, which is associated with a change in lipid profile, as well as with the inheritance and incidence rate of MetS among these patients.
Findings suggest that 5alpha-reductases (5-AR) isoenzymes could be explored as a therapeutic target for urothelial bladder cancer (UBC) with 5alpha-reductase inhibitors (5-ARI).
we demonstrated that AR, 5alphaR1 and 5alphaR2 immunoreactivity in bladder urothelial carcinoma cells significantly decreased with advanced tumor grade.
Studies indicate that enhanced 5alpha-reductase activity in subjects with polycystic ovary syndrome (PCOS) was associated with insulin resistance (IR) rather than obesity.
Although 4-dione is the main source of 5alpha-dihydrotestosterone in human preadipocytes, production of this steroid by 5 alpha-reductase isoenzymes (SRD5A1, 2 and 3) mediates the inhibitory effect of both 4-dione and testosterone on preadipocyte differentiation.
SRD5A1 small-interfering RNA knockdown led to significant increase in progesterone receptor-B nuclear import, ectopic, whereas SRD5A1 overexpression resulted in remarkable inhibition of nuclear progesterone receptor-B in P4-treated cells. Repression of SRD5A1 activated progesterone receptor-B responsive gene, whereas overexpression of SRD5A1 possessed an inhibitory effect.
the genotypic distribution of 22 single nucleotide polymorphisms in SRD5A1 and SRD5A2 in a set of Spanish prostate cancer patients, were evaluated.
A total of 2 SNPs in SRD5A1-rs3822430 and rs1691053-were associated with prostate-specific antigen level at diagnosis.
study found SRD5A enzyme is present in spermatozoa and that its cellular content is lowered in sperm samples from varicocele patients compared to healthy subjects
Results show that 5alpha-reductase type 1 was associated with intratumoral dihydrotestosterone concentrations and is an independent prognostic factor in endometrioid endometrial adenocarcinoma.
In model cell lines of endometrial cancer, AKR1C2 and SRD5A1 have crucial roles in progesterone metabolism.
Increased 5alphaR activity and glucocorticoid secretion rate over time are linked with the development of metabolic disease, and may represent targets for therapeutic intervention.
SRD5A1 rs166050C risk variant was associated with greater prostatic exposure to androsterone
Significantly higher levels of SRD5A1, AKR1C2, AKR1C3, and HSD17B10 mRNA were however found in bone metastases than in non-malignant and/or malignant prostate tissue
SRD5A1 and SRD5A2 single nucleotide polymorphisms are significantly associated with the clinical characteristics of benign prostatic hyperplasia and the efficacy of benign prostatic hyperplasia treatment.
Different effects were seen for progesterone, which significantly decreased SRD5A1 protein levels.
Postmenopausal breast cancer risk associated with combined therapy may be modified by genetic variation in SRD5A1
Based on a limited selection of gene variants, no involvement of SRD5A1, SRD5A2, ESR1, ESR2 or PGR in female pattern hair loss is evident.
The different expression levels of 5alpha-reductase isoenzymes may confer response or resistance to 5alpha-reductase inhibitors.
Ten percent of cases and 44% of controls had the cytosine/cytosine (C/C) genotype for the SRD5A1 SNP, rs501999 indicating that this genotype may protect women against severe premenstrual symptoms.
Steroid 5-alpha-reductase (EC 188.8.131.52) catalyzes the conversion of testosterone into the more potent androgen, dihydrotestosterone (DHT). Also see SRD5A2 (MIM 607306).
, 3-oxo-5-alpha-steroid 4-dehydrogenase 1
, SR type 1
, steroid 5-alpha-reductase 1
, type 1 5alpha-reductase
, 3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1
, 5-alpha reductase
, steroid 5-alpha-reductase type I
, steroid 5 alpha-reductase 1
, prostatic steroid 5-alpha-reductase type I
, 3-oxo-5-alpha-steroid 4-dehydrogenase 1-like